Stratification and prognostic relevance of Jass's molecular classification of colorectal cancer

Frontiers in Oncology

Volumn 2, Issue FEB, 2012, Pages

  Zlobec, Inti ^a,b   Bihl, Michel P ^b   Foerster, Anja ^b   Rufle, Alex ^b   Terracciano, Luigi ^b   Lugli, Alessandro ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

BRAF; Colorectal cancer; CpG island methylator phenotype; DNA methylation; Prognosis

Indexed keywords

B RAF KINASE; BISULFITE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NEUROGENIN 1; PROTEIN MLH1;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA ISOLATION; DNA METHYLATION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR BIOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PYROSEQUENCING; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84868144489     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00007     Document Type: Article

References (28)

1. Ahn, J. B., Chung, W. B., Maeda, O., Shin, S. J., Kim, H. S., Chung, H. C., Kim, N. K., and Issa, J. P. (2011). DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117, 1847-1854.
2. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R., and Clarke, P. A. (1998). Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J. Natl. Cancer Inst. 90, 675-684.
3. Boland, C. R., and Goel, A. (2010). Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073-2087, e3.
4. Colella, S., Shen, L., Baggerly, K. A., Issa, J. P., and Krahe, R. (2003). Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35, 146-150.
5. Curtin, K., Slattery, M. L., and Samowitz, W. S. (2011). CpG island methylation in colorectal cancer: past, present and future. Patholog. Res. Int. 2011, 902674.
6. Dahlin, A. M., Palmqvist, R., Henriksson, M. L., Jacobsson, M., Eklof, V., Rutegard, J., Oberg, A., and Van Guelpen, B. R. (2010). The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res. 16, 1845-1855.
7. Issa, J. P. (2000). CpG-island methylation in aging and cancer. Curr. Top. Microbiol. Immunol. 249, 101-118.
8. Jass, J. R. (1986). Lymphocytic infiltration and survival in rectal cancer. J. Clin. Pathol. 39, 585-589.
9. Jass, J. R. (2007). Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50, 113-130.
10. Jover, R., Nguyen, T. P., Perez-Carbonell, L., Zapater, P., Paya, A., Alenda, C., Rojas, E., Cubiella, J., Balaguer, F., Morillas, J. D., Clofent, J., Bujanda, L., Reñé, J. M., Bessa, X., Xicola, R. M., Nicolás-Pérez, D., Castells, A., Andreu, M., Llor, X., Boland, C. R., and Goel, A. (2011). 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140, 1174-1181.
11. Kim, J. C., Choi, J. S., Roh, S. A., Cho, D. H., Kim, T. W., and Kim, Y. S. (2010). Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann. Surg. Oncol. 17, 1767-1776.
12. Kim, J. H., Shin, S. H., Kwon, H. J., Cho, N. Y., and Kang, G. H. (2009). Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 455, 485-494.
13. Kloor, M., Michel, S., and von Knebel Doeberitz, M. (2010). Immune evasion of microsatellite unstable colorectal cancers. Int. J. Cancer 127, 1001-1010.
14. Lee, S., Cho, N. Y., Yoo, E. J., Kim, J. H., and Kang, G. H. (2008). CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch. Pathol. Lab. Med. 132, 1657-1665.
15. Nosho, K., Irahara, N., Shima, K., Kure, S., Kirkner, G. J., Schernhammer, E. S., Hazra, A., Hunter, D. J., Quackenbush, J., Spiegelman, D., Giovannucci, E. L., Fuchs, C. S., and Ogino, S. (2008). Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 3, e3698. doi:10.1371/journal.pone.0003698
16. Ogino, S., Cantor, M., Kawasaki, T., Brahmandam, M., Kirkner, G. J., Weisenberger, D. J., Campan, M., Laird, P. W., Loda, M., and Fuchs, C. S. (2006). CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 55, 1000-1006.
17. Ogino, S., Kawasaki, T., Kirkner, G. J., Kraft, P., Loda, M., and Fuchs, C. S. (2007). Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J. Mol. Diagn. 9, 305-314.
18. Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M., Giovannucci, E. L., and Fuchs, C. S. (2009). CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90-96.
19. Potapova, A., Albat, C., Hasemeier, B., Haeussler, K., Lamprecht, S., Suerbaum, S., Kreipe, H., and Lehmann, U. (2011). Systematic cross-validation of 454 sequencing and pyrosequencing for the exact quantification of DNA methylation patterns with single CpG resolution. BMC Biotechnol. 11, 6. doi:10.1186/1472-6750-11-6
20. Samowitz, W. S., Albertsen, H., Sweeney, C., Herrick, J., Caan, B. J., Anderson, K. E., Wolff, R. K., and Slattery, M. L. (2006). Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J. Natl. Cancer Inst. 98, 1731-1738.
21. Sanchez, J. A., Krumroy, L., Plummer, S., Aung, P., Merkulova, A., Skacel, M., DeJulius, K. L., Manilich, E., Church, J. M., Casey, G., and Kalady, M. F. (2009). Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br. J. Surg. 96, 1196-1204.
22. Shima, K., Morikawa, T., Baba, Y., Nosho, K., Suzuki, M., Yamauchi, M., Hayashi, M., Giovannucci, E., Fuchs, C. S., and Ogino, S. (2011). MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 22, 301-309.
23. Tost, J., Dunker, J., and Gut, I. G. (2003). Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 35, 152-156.
24. Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., and Issa, J. P. (1999). CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 96, 8681-8686.
25. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., Fishel, R., Lindor, N. M., Burgart, L. J., Hamelin, R., Hamilton, S. R., Hiatt, R. A., Jass, J., Lindblom, A., Lynch, H. T., Peltomaki, P., Ramsey, S. D., Rodriguez-Bigas, M. A., Vasen, H. F., Hawk, E. T., Barrett, J. C., Freedman, A. N., and Srivastava, S. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 96, 261-268.
26. Van Rijnsoever, M., Elsaleh, H., Joseph, D., McCaul, K., and Iacopetta, B. (2003). CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 9, 2898-2903.
27. Ward, R. L., Cheong, K., Ku, S. L., Meagher, A., O'Connor, T., and Hawkins, N. J. (2003). Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J. Clin. Oncol. 21, 3729-3736.
28. Yu, J., Freimuth, R. R., Culverhouse, R., Marsh, S., Watson, M. A., and McLeod, H. L. (2008). DNA methylotype analysis in colorectal cancer. Oncol. Rep. 20, 921-927.